HOME >> MEDICINE >> NEWS
Small molecule found to mimic key nerve growth factors; May eventually be used in treatment of brain disorders

Washington, DC--Scientists have found that a small, naturally-occurring molecule that enters the brain easily keeps nerve cells alive by stimulating the actions of growth factors. This points the way for the potential use in the future of small molecules to approach a number of disorders, which may include Alzheimers disease, spinal cord injury and Lou Gehrigs disease.

We have discovered that a small molecule called adenosine can mimic the effects of nerve growth factor and brain-derived growth factor to prevent cell death in the nervous system, says Moses Chao, PhD, a neurobiologist at New York University. Such growth factors serve as survival agents for nerve cells, keeping them alive. Chaos study, funded primarily by the National Institutes of Health, appears in the March 13 issue of The Proceedings of the National Academy of Sciences. This is important because although there are many potential uses for growth factors for treatment of diseases, they are difficult to deliver. In contrast, small molecules such as adenosine are easy to deliver, says Lloyd Greene, PhD, a neuroscientist and professor of pathology at Columbia University.

Using rat nerve cells isolated from the hippocampus, a brain area involved in learning and memory, and grown in the laboratory, Chao found that adenosine was able to communicate with receptors for brain-derived growth factor. This resulted in the production of the signals that prevented neurons from dying.

These results suggest that there may be other small molecules that work like adenosine. The next steps are to test adenosine compounds in animal models of human diseases.


'"/>

Contact: Joe Carey
joe@sfn.org
202-745-5138
Society for Neuroscience
5-Mar-2001


Page: 1

Related medicine news :

1. Small increases or blips in HIV levels do not signal mutations leading to drug-resistant HIV
2. Rices CNST awards Smalley/Curl funds for innovation
3. Small steps toward coverage
4. Small band of nurses plays key role keeping germ threats at bay
5. Small social circles tied to heart disease death in women
6. Small study shows SAMe may improve treatment of depression
7. South Floridas Small wins The Gerontological Society of Americas 2004 Margret M. Baltes Award
8. Smallpox vaccine can be diluted and still be effective, expanding supply if needed
9. Small, frequent doses of caffeine best strategy for staying awake
10. New study: Small, frequent doses of caffeine best strategy for staying awake
11. Small uterine fibroids may be linked with increased risk of miscarriage, early study results show

Post Your Comments:
(Date:5/20/2013)... When people have lap ... become a celebrity. New Jersey governor Chris Christie, ... report (“Chris Christie Says Lap Band Surgery Is ... surgery was not done so that he could ... as a former lap band patient. Simply put, ...
(Date:5/20/2013)... Fountain Valley, CA (PRWEB) May 20, 2013 ... few dental professionals certified and trained to use the ... surgery designed to treat patients with gum disease. ... already lost teeth due to gum disease restore the ... disease begins with the buildup of plaque and tartar ...
(Date:5/20/2013)... 20, 2013 Mombo from Comfort ... conference of the US Lactation Consultant Association (USLCA) May ... nurses, doctors and other health professionals. , The ... helping lactation professionals discover and learn about the latest ... the most popular nursing pillows, which new mothers use ...
(Date:5/20/2013)... According to a May 6, 2013 CBS News article, ... tanning salons in the US may soon have to ... to see cancer warnings on indoor tanning beds ... for the use of indoor tanning and sun beds. The ... increasingly common over the last few decades (Go to goo.gl/TCT6m). ...
(Date:5/20/2013)... According to a June 2009 Bloomberg article, it ... to approximately $3.6 billion dollars per year (i). ... that there 15 million incidents of medical harm each ... who receives any form of medical treatment should be ... defines malpractice as “a dereliction of professional duty or ...
Breaking Medicine News(10 mins):Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 2Health News:The Lap Band Center: Dr. Atul Madan Applauds Chris Christie's Dedication to Family and Loss of 30 Pounds After Lap Band Surgery 3Health News:Fountain Valley, Ca Gum Disease Patients with Missing Teeth Can Now Receive Laser Gum Surgery from Dr. Robert Mokbel for Success with Dental Implants 2Health News:Comfort & Harmony™ Exhibited mombo™ Nursing Pillow at USLCA’s First Inaugural Conference 2Health News:Tanning - FDA Wants Tanning Salons to Post Cancer Warning Signs 2Health News:Law Firm Releases New Informational Graphic on the Basics of Understanding Medical Malpractice Cases 2
(Date:5/20/2013)... , May 20, 2013  Neuralstem, Inc. (NYSE ... , MD, PhD, principal investigator, presented updated Phase ... cell (NSI-566) trial in the treatment of amyotrophic lateral ... disease) at the neuro diabetes special medical symposium in ... a talk called "Recent Therapeutic Advances in Stem Cell ...
(Date:5/20/2013)... 2013  AbbVie (NYSE: ABBV ) ... clinical study called SONAR (Study Of Diabetic Nephropathy ... investigational compound atrasentan - when added to standard of ... with stage 2 to 4 chronic kidney disease ... large, multinational, double-blind, placebo-controlled clinical study that is ...
(Date:5/20/2013)... 20, 2013 With herbal medicines relied upon ... the U.S. Pharmacopeial Convention (USP) will provide freely available ... herbal ingredients used in these products. Today, USP proposes ... new Herbal Medicines Compendium ( HMC ) ... hmc.usp.org . HMC will provide ...
Breaking Medicine Technology:Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 2Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 3Neuralstem ALS Trial Principal Investigator, Dr. Eva Feldman, Presented Phase I Data At The Neuro Diabetes Medical Symposium In Romania 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 2New Compendium Offers Freely Available Testing Standards to Help Ensure the Quality of Herbal Ingredients Used in Traditional Medicines 3
Cached News: